DalCor Pharmaceuticals

ReCode Therapeutics , on track with its plan to take its two lead programs into the clinic this year, announced on 19 September that it raised another $50m in series B venture capital, bringing the ro

Some of the biggest names in biopharma took their best shot at cholesteryl ethyl transfer protein (CETP) inhibition to reduce LDL cholesterol and the risk of cardiovascular disease a decade ago or mor

DalCor Pharmaceuticals says it's still confident about its dal-GenE outcomes study of genetically selected patients treated with the cholesterol-modulating CETP inhibitor dalcetrapib, but the odds on

Nordic Nanovector ASA has announced that Luigi Costa will step down as chief executive officer by mutual agreement with the board following a further delay in the development of its key product